Sorry, you need to enable JavaScript to visit this website.
For the short-term, non-continuous treatment of mild to moderate eczema (atopic dermatitis) not well controlled on topical therapies in people 12 and older without weakened immune systems or when those therapies are not recommended.

The resources you need. The treatment you deserve.

The resources you need. The treatment you deserve.

Unsure where to start when it comes to treating your eczema? We can point you in the right direction. Whether it’s finding a dermatologist or guiding a conversation at your next appointment, the tools and resources below can help you every step of the way.

Take the facts with you

Access all kinds of information about OPZELURA by downloading the patient
brochure in your preferred language below. You can take it to your next doctor’s
appointment or simply hold on to it for a refresher anytime you want.

Image of OPZELURA Patient Brochure
OPZELURA Copay Savings Card

See how you can save
with a copay card

Eligible* patients with commercial insurance may pay as
little as $10 per tube for OPZELURA with a Copay Savings
Card. There are 3 ways to get a card—download your card
directly, send it to your email, or get it in a text!

*Terms & Conditions apply

Learn More
OPZELURA Copay Savings Card
Need help connecting with a dermatologist?

Finding the right kind of treatment for your skin begins by establishing
a relationship with a dermatologist—and this Zocdoc* tool can help you find
one. Enter your ZIP code below to see a list of local dermatologists or to
connect with one virtually.

Find a dermatologist

*Please note that the list of physicians provided is generated by Zocdoc and not by Incyte Corporation.

Help prepare with
eczema eight

When it comes to making the most of your next dermatology appointment, a little preparation can go a long way. The Eczema Eight* can help you identify and share the ways eczema impacts you. Alongside your dermatologist, you can talk through the right treatment plan for you.

*Please note that the Eczema Eight is not an official tool used to measure eczema severity or burden.

A closer look at OPZELURA with Dr. Rocco Serrao

A big part of feeling confident in your eczema treatment is understanding
the way it works in your body. Watch the video below to learn from a
dermatologist how OPZELURA is thought to work to provide relief you can
see and feel on mild to moderate eczema.

Watch The Video
Indication and Usage

OPZELURA is a prescription medicine
used on the skin (topical) for
short-term and non-continuous
treatment of mild to moderate
eczema (atopic dermatitis)
in non-immunocompromised people
12 and older whose disease is not
well controlled with topical
prescription therapies or when those
therapies are not recommended.

The use of OPZELURA along with
therapeutic biologics for atopic
dermatitis, other JAK inhibitors, or
strong immunosuppressants such
as azathioprine or cyclosporine is
not recommended.

Important Safety Information

OPZELURA cream is for use on the skin only. Do not use OPZELURA cream, in your eyes, mouth or vagina.

OPZELURA may cause serious side effects, including:

Serious Infections: OPZELURA cream contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA.

OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA.

Increased risk of death from all causes, including sudden cardiac death, has happened in people taking JAK inhibitors by mouth.

Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Some people have had lymphoma and other cancers while taking JAK inhibitors by mouth, especially if they are a current or past smoker. Some people have had skin cancers while taking OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA.

There is an increased risk of major cardiovascular events such as heart attack, stroke or cardiac death in people with cardiovascular risk factors and who are current or past smokers while using JAK inhibitors to treat inflammatory conditions.

Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening.

Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen.

Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or triglycerides.

Before starting OPZELURA, tell your healthcare provider if you:

  • have an infection, are being treated for one, or have an infection that keeps coming back
  • have diabetes, chronic lung disease, HIV, or a weak immune system
  • have or had TB, or have been in close contact with someone with TB
  • have had shingles (herpes zoster) or hepatitis B or C
  • live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
  • think you have an infection or have symptoms of an infection such as:
  • fever, sweating, or chills
  • muscle aches
  • cough or shortness of breath
  • blood in your phlegm
  • weight loss
  • warm, red, or painful skin or sores on your body
  • diarrhea or stomach pain
  • burning when you urinate or urinating more often than usual
  • feeling very tired
  • have ever had any type of cancer, or are a current or past smoker
  • have had blood clots in the veins of your legs or lungs in the past
  • have high cholesterol or triglycerides
  • have or have had low white or red blood cell counts
  • are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation at 1-855-463-3463.
  • are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose.

After starting OPZELURA:

  • Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have.
  • Get emergency help right away if you have any symptoms of a heart attack or stroke while using OPZELURA, including:
  • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw, or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded
  • weakness in one part or on one side of your body
  • slurred speech
  • Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OPZELURA, including: swelling, pain or tenderness in one or both legs, sudden, unexplained chest or upper back pain, or shortness of breath or difficulty breathing.
  • Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath or fever.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of OPZELURA include: pain or swelling in your nose or throat (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).

These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Incyte Corporation at 1-855-463-3463.

Please see the Full Prescribing Information, including Boxed Warning, and Medication Guide for OPZELURA.